HIF-1α and GLUT1 Gene Expression is Associated with Chemoresistance of Acute Myeloid Leukemia

  • Song, Kui (Department of Hematology, Nanfang Hospital of Southern Medical University) ;
  • Li, Min (Department of Pharmacy, The First Affiliated Hospital of Jishou University) ;
  • Xu, Xiao-Jun (Department of Hematology, Nanfang Hospital of Southern Medical University) ;
  • Xuan, Li (Department of Hematology, Nanfang Hospital of Southern Medical University) ;
  • Huang, Gui-Nian (Department of Hematology, Zhongshan City People's Hospital) ;
  • Song, Xiao-Ling (Department of Hematology, Nanfang Hospital of Southern Medical University) ;
  • Liu, Qi-Fa (Department of Hematology, Nanfang Hospital of Southern Medical University)
  • Published : 2014.02.28


Aims: Much evidence suggests that increased glucose metabolism in tumor cells might contribute to the development of acquired chemoresistance. However, the molecular mechanisms are not fully clear. Therefore, we investigated a possible correlation of mRNA expression of HIF-$1{\alpha}$ and GLUT1 with chemoresistance in acute myeloid leukemia (AML). Methods: Bone marrow samples were obtained from newly diagnosed and relapsed AML (M3 exclusion) cases. RNA interference with short hairpin RNA (shRNA) was used to stably silence GLUT1 or HIF-$1{\alpha}$ gene expression in an AML cell line and HIF-$1{\alpha}$ and GLUT1 mRNA expression was measured by real-time quantitative polymerase chain reaction assay (qPCR). Results: High levels of HIF-$1{\alpha}$ and GLUT1 were associated with poor responsiveness to chemotherapy in AML. Down-regulation of the expression of GLUT1 by RNA interference obviously sensitized drug-resistant HL-60/ADR cells to adriamycin (ADR) in vitro, comparable with RNA interference for the HIF-$1{\alpha}$ gene. Conclusions: Our data revealed that over-expression of HIF-$1{\alpha}$ and GLUT1 might play a role in the chemoresistance of AML. GLUT1 might be a potential target to reverse such drug resistance.


  1. Amann T, Hellerbrand C (2009). GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets, 13, 1411-27.
  2. Amann T, Maegdefrau U, Hartmann A, et al (2009). GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol, 174, 1544-52.
  3. Bayley JP, Devilee P (2012). The Warburg effect in 2012. Curr Opin Oncol, 24, 62-7.
  4. Buentke E, Nordstrom A, Lin H, et al (2011). Glucocorticoidinduced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. Blood Cancer J, 1, e31.
  5. Cao X, Fang L, Gibbs S, et al (2007). Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol, 59, 495-505.
  6. Chen CY, Jia JH, Zhang MX, et al (2005). Proteomic analysis on multi-drug resistant cells HL-60/DOX of acute myeloblastic leukemia. Chin J Physiol, 48, 115-20.
  7. Chen EI (2012). Mitochondrial dysfunction and cancer metastasis. J Bioenerg Biomembr, 44, 619-22.
  8. Chinese Chemotherapy Symposium of Leukemia (1988). The chemotherapy response criteria of acute leukemia. Chin J Hematol, 9, 183-4.
  9. Chung FY, Huang MY, Yeh CS, et al (2009). GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer, 9, 241.
  10. Comito G, Calvani M, Giannoni E, et al (2011). HIF-1$\alpha$ stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med, 51, 893-904.
  11. Deeb G, Vaughan MM, McInnis I, et al (2011). Hypoxiainducible factor-1$\alpha$ protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res, 35, 579-84.
  12. Deeb G, Vaughan MM, McInnis I, et al (2011). Hypoxiainducible factor-1$\alpha$ protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res, 35, 579-84.
  13. Hao J, Song X, Song B, et al (2008). Effects of lentivirusmediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther, 15, 449-55.
  14. Herst PM, Howman RA, Neeson PJ, et al (2011). The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J Leukoc Biol, 89, 51-5.
  15. Hu Y, Kirito K, Yoshida K, et al (2009). Inhibition of hypoxiainducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther, 8, 2329-38.
  16. Huang XD, Wang ZF, Dai LM, et al (2012). Microarray analysis of the hypoxia-induced gene expression profile in malignant C6 glioma cells. Asian Pac J Cancer Prev, 13, 4793-9.
  17. Hulleman E, Kazemier KM, Holleman A, et al (2009). Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 113, 2014-21.
  18. Kluza J, Jendoubi M, Ballot C, et al (2011). Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS One, 6, e21924.
  19. Kominsky DJ, Klawitter J, Brown JL, et al (2009). Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res, 15, 3442-50.
  20. Lu CW, Lin SC, Chen KF, et al (2008). Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem, 283, 28106-14.
  21. Manel N, Battini JL, Sitbon M (2005). Human T cell leukemia virus envelope binding and virus entry are mediated by distinct domains of the glucose transporter GLUT1. J Biol Chem, 280, 29025-9.
  22. Matsunaga T, Imataki O, Torii E, et al (2012). Elevated HIF- 1$\alpha$ expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res, 36, e122-4.
  23. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, et al (2007). Energy metabolism in tumor cells. FEBS J, 274, 1393-418.
  24. Nakajima EC, Van Houten B (2013). Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog, 52, 329-37.
  25. Papageorgis P, Cheng K, Ozturk S, et al (2011). Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res, 71, 998-1008.
  26. Patiar S, Harris AL (2006). Role of hypoxia-inducible factor- 1alpha as a cancer therapy target. Endocr Relat Cancer, 13, S61-75.
  27. Pelicano H, Martin DS, Xu RH, et al (2006). Glycolysis inhibition for anticancer treatment. Oncogene, 25, 4633-46.
  28. Robey IF, Lien AD, Welsh SJ, et al (2005). Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia, 7, 324-30.
  29. Saigusa S, Toiyama Y, Tanaka K, et al (2012). Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today, 42, 460-9.
  30. Song X, Liu X, Chi W, et al (2006). Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol, 58, 776-84.
  31. Suh DH, Kim MK, No JH, et al (2011). Metabolic approaches to overcoming chemoresistance in ovarian cancer. Ann N Y Acad Sci, 1229, 53-60.
  32. Takubo K, Goda N, Yamada W, et al (2010). Regulation of the HIF-1a level is essential for hematopoietic stem cells. Cell Stem Cell, 7, 391-402.
  33. Tamada M, Nagano O, Tateyama S, et al (2012). Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res, 72, 1438-48.
  34. Wynn ML, Merajver SD, Schnell S (2012). Unraveling the complex regulatory relationships between metabolism and signal transduction in cancer. Adv Exp Med Biol, 736, 179-89.
  35. Zhou Y, Tozzi F, Chen J, et al (2012). Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res, 72, 304-14.
  36. Zhou Y, Tozzi F, Chen J, et al (2012). Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res, 72, 304-14.

Cited by

  1. Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity vol.37, pp.2, 2016,
  2. gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma vol.12, pp.10, 2017,
  3. MicroRNA-124 suppresses proliferation and glycolysis in non–small cell lung cancer cells by targeting AKT–GLUT1/HKII vol.39, pp.5, 2017,
  4. Chemoresistance and the Self-Maintaining Tumor Microenvironment vol.10, pp.12, 2018,
  5. The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought vol.6, pp.2296-634X, 2018,
  6. Polymorphism rs1385129 Within Glut1 Gene SLC2A1 Is Linked to Poor CD4+ T Cell Recovery in Antiretroviral-Treated HIV+ Individuals vol.9, pp.1664-3224, 2018,